Drug (ID: DG00342) and It's Reported Resistant Information
Name
Pertuzumab
Synonyms
Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)
    Click to Show/Hide
Indication
In total 1 Indication(s)
Breast cancer [ICD-11: 2C60]
Approved
[1]
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
Breast cancer [ICD-11: 2C60]
[1]
Target Erbb2 tyrosine kinase receptor (HER2) ERBB2_HUMAN [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
TTD Drug ID
D0CI4E
DrugBank ID
DB06366
Type(s) of Resistant Mechanism of This Drug
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Breast cancer [ICD-11: 2C60]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) [1]
Molecule Alteration Missense mutation
p.V1676A
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
Cell Pathway Regulation Notch signaling pathway Regulation hsa04330
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) [1]
Molecule Alteration Missense mutation
p.V1599M
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
Cell Pathway Regulation Notch signaling pathway Regulation hsa04330
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) [1]
Molecule Alteration Missense mutation
p.S1689P
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
Cell Pathway Regulation Notch signaling pathway Regulation hsa04330
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Nras (NRAS) [1]
Molecule Alteration Missense mutation
p.V14A
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Nras (NRAS) [1]
Molecule Alteration Missense mutation
p.F78L
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Nras (NRAS) [1]
Molecule Alteration Missense mutation
p.F28S
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Nras (NRAS) [1]
Molecule Alteration Missense mutation
p.A66T
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: DNA mismatch repair protein Mlh1 (MLH1) [1]
Molecule Alteration Missense mutation
p.V345A
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: DNA mismatch repair protein Mlh1 (MLH1) [1]
Molecule Alteration Missense mutation
p.R90Q
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: DNA mismatch repair protein Mlh1 (MLH1) [1]
Molecule Alteration Missense mutation
p.R74Q
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: DNA mismatch repair protein Mlh1 (MLH1) [1]
Molecule Alteration Missense mutation
p.A348V
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Hras (HRAS) [1]
Molecule Alteration Missense mutation
p.V9A
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Hras (HRAS) [1]
Molecule Alteration Missense mutation
p.T2A
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Hras (HRAS) [1]
Molecule Alteration Missense mutation
p.S17N
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Hras (HRAS) [1]
Molecule Alteration Missense mutation
p.Q61X
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Hras (HRAS) [1]
Molecule Alteration Missense mutation
p.N26S
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Hras (HRAS) [1]
Molecule Alteration Missense mutation
p.G12S
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: GTPase Hras (HRAS) [1]
Molecule Alteration Missense mutation
p.D54N
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) [1]
Molecule Alteration Missense mutation
p.R216L
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) [1]
Molecule Alteration Missense mutation
p.R216C
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) [1]
Molecule Alteration Missense mutation
p.R186H
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) [1]
Molecule Alteration Missense mutation
p.N203S
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) [1]
Molecule Alteration Missense mutation
p.M206V
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) [1]
Molecule Alteration Missense mutation
p.D214N
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) [1]
Molecule Alteration Missense mutation
p.D181G
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.V292E
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.R705G
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.L760F
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.K284E
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.I706T
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.G696E
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.A822V
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.V292M
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.P741S
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.G288D
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Missense mutation
p.E711K
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Cadherin-1 (CDH1) [1]
Molecule Alteration Missense mutation
p.A348V
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Cadherin-1 (CDH1) [1]
Molecule Alteration Missense mutation
p.V345A
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Cadherin-1 (CDH1) [1]
Molecule Alteration Missense mutation
p.R90Q
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
Key Molecule: Cadherin-1 (CDH1) [1]
Molecule Alteration Missense mutation
p.R74Q
Resistant Disease HER2 positive breast cancer [ICD-11: 2C60.8]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Plasma Blood Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Next-generation sequencing assay; Circulating-free DNA assay
Experiment for
Drug Resistance
Positron emission tomography/Computed tomography assay
Mechanism Description Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy.
References
Ref 1 Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer. Chin Med J (Engl). 2017 Mar 5;130(5):522-529. doi: 10.4103/0366-6999.200542.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.